Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer

NCT01010126 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01010126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01010126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
September 8, 2009
Completion date
March 13, 2017
Enrollment
252 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

adult hepatocellular carcinoma, advanced adult hepatocellular carcinoma, endometrial serous adenocarcinoma, localized non-resectable adult liver carcinoma, lung carcinoid tumor, malignant pancreatic gastrinoma, malignant pancreatic glucagonoma, malignant pancreatic insulinoma, malignant pancreatic somatostatinoma, metastatic digestive system neuroendocrine tumor g1, ovarian carcinosarcoma, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous surface papillary adenocarcinoma, pancreatic alpha cell adenoma, pancreatic beta cell adenoma, pancreatic delta cell adenoma, pancreatic g-cell adenoma, pancreatic polypeptide tumor, recurrent adult liver carcinoma, recurrent digestive system neuroendocrine tumor g1, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent pancreatic neuroendocrine carcinoma, recurrent primary peritoneal carcinoma, recurrent uterine corpus carcinoma, regional digestive system neuroendocrine tumor g1, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiia uterine corpus cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiib uterine corpus cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iiic uterine corpus cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer, stage iva uterine corpus cancer, stage ivb uterine corpus cancer, uterine carcinosarcoma